MedTrace Logo

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

NCT03647215 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 427

Last updated 2021-08-16

No results posted yet for this study

Summary

A multicenter, prospective cohort study of the mutation status of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are being treated with first or subsequent tyrosine kinase inhibitor (TKI) therapy in the UK, Ireland, or France.

Conditions

  • Chronic Phase Chronic Myelogenous Leukemia
  • Accelerated Phase Chronic Myelogenous Leukemia
  • Blastic Phase Chronic Myelogenous Leukemia
  • Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Sponsors & Collaborators

  • Incyte Biosciences UK

    lead INDUSTRY

Principal Investigators

  • Michael Thompson, MD · Incyte Biosciences UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-18
Primary Completion
2021-03-31
Completion
2021-06-30

Countries

  • Ireland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03647215 on ClinicalTrials.gov